Rexahn Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company's clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance. RX-3117 is a small molecule nucleoside compound with an anti-metabolite mechanism of action and has therapeutic potential in a range of cancers, including pancreatic, bladder, colon and lung cancer. Supinoxin is a small molecule inhibitor of phosphorylation of p68. The Company also has a drug candidate RX-21101, an N-(2-Hydroxypropyl) methacrylamide-docetaxel-folate, in pre-clinical development. The Company is working on research technologies, including multi-target aimed ligands platform and nano-based drug delivery systems.
